In sickle cell trait (SCT), hemoglobin A (HbA) and S (HbS) are co-expressed in each red blood cell (RBC). While homozygous expression of HbS (HbSS) leads to polymerization and sickling of RBCs resulting in sickle cell disease (SCD) characterized by hemolytic anemia, painful vaso-occlusive episodes and shortened life-span, SCT is considered a benign condition usually with minor or no complications related to sickling. However, physical activities that cause increased tissue oxygen demand, dehydration and/or metabolic acidosis leads to increased HbS polymerization and life-threatening complications including death. We report that GBT440, an agent being developed for the treatment of SCD, increases the affinity of oxygen for Hb and inhibits in vitro polymerization of a mixture of HbS and HbA that simulates SCT blood. Moreover, GBT440 prevents sickling of SCT blood under in vitro conditions mimicking strenuous exercise with hypoxia, dehydration and acidosis. Together, our results indicate that GBT440 may have the potential to protect SCT individuals from sickling-related complications during conditions that favor HbS polymerization.
Introduction
Sickle cell trait (SCT) is characterized by the inheritance of normal and sickle -globin alleles resulting in the expression of both hemoglobin A (HbA) and S (HbS) in red blood cells (RBCs) . It is estimated that 300 million people worldwide have SCT, with the highest prevalence of approximately 30 to 40% in subSaharan Africa. 1 A complex and potentially lifethreatening pathophysiology is usually linked to the expression of HbS due to polymerization of deoxygenated HbS (deoxy-HbS) which causes sickling and damage of RBCs. For example, in sickle cell disease (SCD) where both alleles of the β-globin gene carry the sickle mutation, HbS constitutes almost all of the total Hb expressed within RBCs. As a consequence, polymerization of deoxy-HbS and sickling of RBCs occurs frequently leading to occlusion of tissue capillaries, hemolytic anemia, ischemic tissue injury, progressive end organ damage and premature death in SCD. 2 In contrast to SCD, SCT is not viewed as a disease state because its complications are minor or rare. 1, 3, 4 With typically <1% circulating sickled RBCs, SCT individuals rarely experience complications related to sickling. 5 These benign clinical observations are most likely attributed to the significant expression of HbA within RBCs. On the average, HbA accounts for ~60% of the total hemoglobin expressed in SCT RBCs. 1 HbA inhibits polymerization of deoxyHbS, thus minimizing sickling and related complications. 6 However, activities or processes that causes hypoxia, dehydration, acidosis, hypothermia, increased RBC 2.3-DPG concentration and hyperosmolality of blood can increase sickling in SCT individuals. 1, 7 For example, strenuous exercise (especially at high altitudes) induces severe hypoxemia, metabolic acidosis, hyperthermia, and red-cell dehydration, all of which promote exertional sickling resulting in serious morbidity. 3, 4, [8] [9] [10] Exertional sickling and rhabdomyolysis have potentially led to the sudden death of soldiers and athletes with SCT. [11] [12] [13] Other sickling related complications include splenic infarction, exertional heat illness (heat stroke and renal failure), increased urinary tract infections in women, gross hematuria, hyposthenuria, and hyphemia. 3, 10 Thus, although SCT is generally considered benign, it is important to manage HbS polymerization and sickling in SCT individuals during strenuous physical exertion or under conditions that promote sickling-related complications. Currently, there is no therapeutic option to prevent sickling-related complications in SCT.
GBT440, an allosteric modifier of Hb oxygen (Hb-O 2 ) affinity, is a novel anti-sickling agent that is being developed for the treatment of SCD. 14 GBT440 increases Hb-O 2 affinity, delays polymerization of deoxy-HbS and prevents in vitro sickling of sickle RBCs (SSRBCs). 14 In this study, we show that GBT440 inhibits polymerization of a mixture of HbS and HbA. In addition, we demonstrate that GBT440 prevents sickling of SCT blood under in vitro conditions mimicking strenuous exercise with hypoxia, dehydration and acidosis. Together, our results suggest that GBT440 may have the potential to protect SCT individuals from sickling-related complications during conditions that favor HbS polymerization.
Materials and Methods

Blood source
Sodium citrate anticoagulated whole blood from sickle cell patients was obtained from were run on a Tris-glycine 12% acrylamide native gel where they were separated according to their isoelectric point allowing for their identification. Purified HbS or HbA was buffer exchanged into 1.8 M KH 2 PO 4 at pH 7.4, flash frozen with liquid nitrogen and stored at -80°C.
In vitro polymerization
HbS polymerization was evaluated in an adapted version of the in vitro polymerization assay described by Adachi and colleagues (1982) . For all polymerization experiments, 50 µM of Hb (HbS alone or mixture of HbS and HbA) in 1.8 M KH 2 PO 4 at pH 7.4 was used. To evaluate the ability of GBT440 to delay polymerization, HbS was first incubated with GBT440 [prepared in 100% dimethyl sulfoxide (DMSO)] for 1 h at 37 o C. The final DMSO concentration was 0.3%. The Hb solution was deoxygenated in a hypoxic chamber (99.5% N 2 /0.5% O 2 ) for 90 min at 4 o C and polymerization was initiated by increasing the temperature from 4 to 37 o C. Polymerization was measured by the increase in absorbance at 700 nm for 50 min. A plot of the optical density (at 700 nm) on the y-axis against time on the x-axis was generated. The delay time was determined as the timepoint at which the derivative (or slope) of the polymerization curve was equal to +0.02 (a positive slope signifying the point of inflection from the delay phase to the polymer growth phase of the curve).
In vitro sickling of isolated red blood cells
Whole blood (500 µL) from SCT individuals or SCD patients was added to 500 µL of poly(butylene succinate) (PBS) (pH 7.4) and centrifuged (Eppendorf 5430 R centrifuge) at 250 g for 5 min. After centrifugation, the supernatant was discarded. This process was repeated twice after which the resulting packed RBCs (100% Hct) were used for sickling experiments. GBT440 (prepared in 100% DMSO) was added to 40 µL of PBS at a final concentration of 1 mM. The final DMSO concentration was 0.5%. Next, 10 µL of isolated RBCs was added to the PBS to a final Hct of 20%, immediately mixed by pipetting and incubated at radiotherapy (RT) for 30 min or 1h. The RBC/compound reaction mixture was transferred to a 96-well gas permeable plate (cat #8602001, Coy Laboratory Products) and incubated for 0.5 h at 37 o C in a humidified hypoxic chamber (96% N 2 /4% O 2 ). Next, 5 µL of the reaction mixture was added to deoxygenated PBS (200 µL) in a 24-well plate and imaged using a microscope (40× magnification) in the humidified hypoxic chamber. Images were quantitated by manually counting round (unsickled) versus non-round (sickled) or based on circularity using the CellVigene software (VigeneTech, Inc.) designed to quantify sickling.
Whole blood oxygen equilibrium curves and sickling
Oxygen equilibrium curves (OECs) were determined with a Hemox analyzer (TCS Scientific). Whole blood samples were incubated for 1 h at 37°C with various concentrations of GBT440 followed by transfer to the sample chamber of the Hemox analyzer. The samples were first saturated with compressed air and then flushed with pure nitrogen to deoxygenate. The absorbance at wavelengths that correspond to the isosbestic point (570 nm) and deoxy-Hb (560 nm) were recorded as a function of the partial pressure of oxygen (pO 2 ). Data for deoxygenation curves were collected using TCS software. During deoxygenation, RBCs were harvested from the sample chamber at 150, 100, 40, 20, 10 and 3 mm Hg and immediately fixed in 1 mL of 2% glutaraldehyde/PBS solution (previously deoxygenated by bubbling 100% N 2 into solution for 20 seconds and sealing with parafilm) for 30 min at RT prior to morphometric analysis. Images of fixed cells were captured using a light microscope and quantitated by manually counting round (un-sickled) versus non-round (sickled) or by using the CellVigene software. 
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Results
Isolated sickle cell trait red blood cells sickle under severe hypoxic conditions
We previously showed that SSRBCs when incubated for 0.5 h under hypoxic conditions mimicking resting hypoxia (pO 2 of 40 mm Hg). 14 During strenous exercise the pO 2 in metabolically active tissues may decrease below 40 mm Hg, a condition we define as severe hypoxic condition. 16 Figure 1E, F) . In contrast, SCT RBCs only sickled when incubated under severe hypoxic conditions ( Figure  1C ) but not under resting hypoxic conditions ( Figure 1B ).
GBT440 delays polymerization of a mixture of 60% hemoglobin A and 40% hemoglobin S
The tendency of a RBC to sickle in vivo is fundamentally a kinetic phenomenon controlled by polymerization delay time of deoxyHbS relative to RBC transit time through hypoxic tissue capillaries. 17 Polymerization of deoxy-HbS begins with a striking latency period (delay time) followed by abrupt polymer formation. 18, 19 Since deoxy-HbS polymers melt when exposed to an oxygenated environment (such as in the lungs), the highest susceptibility of sickling is during RBC transit through hypoxic tissue capillaries. 17, 18 Thus, when the delay time is longer than RBC transit time through hypoxic tissue capillaries, RBCs do not sickle during circulation. 6, 17 Non-polymerizable HbA delays polymerization of deoxy-HbS by virtue of dilution. 15 However, deoxy-HbA and -HbS hybrids (Hb A/S) can copolymerize to some extent with deoxy-HbS and shorten polymerization delay times, consequently removing the full inhibitory benefit of HbA. 15, 20 GBT440 delays polymerization of deoxy-HbS by increasing the fraction of oxygenated-HbS (oxy-HbS) during deoxygenation. 14 Since oxyHb (oxy-HbA, oxy-HbS or oxy-Hb A/S hybrid) inhibits deoxy-HbS polymerization, we tested the ability of GBT440 to delay in vitro polymerization of a mixture of 60% HbA and 40% HbS, which simulates typical SCT Hb mixture. Compared to 100% HbS which exhibited a delay time of 9 min, the delay time for the HbA/HbS mixture was 19 min (Figure 2) . GBT440 increased the polymerization delay time of the HbA/HbS mixture from 19 to 25 min. Thus, these data demonstrate that GBT440 can extend the polymerization delay time of a SCT mixture of HbA and HbS in vitro.
GBT440 prevents sickling of sickle cell trait blood under severe hypoxic conditions
Since GBT440 can delay polymerization of a SCT mixture of 60% HbA and 40% HbS, we investigated whether GBT440 could inhibit sickling of SCT blood under severe hypoxic conditions. For the sickling assay previously described (Figure 1 ), isolated SCT RBCs were incubated without agitation and under fixed hypoxic conditions for 0.5 h, which is a much longer duration than typical RBC transit times (<1 min) through hypoxic tissue capillaries and venous circulation. 17 For a more physiolog- ically relevant scenario, we determined the anti-sickling activity of GBT440 in SCT blood under variable hypoxic conditions over a shorter duration of time. In vitro sickling of SCT blood was evaluated in a Hemox analyzer followed by morphometric measurements. Using the Hemox analyzer, SCT blood was deoxygenated from 150 mm Hg to 1.6 mm Hg withiñ 10 min, such that on the average, SCT RBCs were exposed to each oxygen tension for less than a minute. During deoxygenation, SCT RBCs were harvested at oxygen tensions of 150, 100, 40, 20, 10 and 3mm Hg and fixed with 2% glutaraldehyde. We observed relatively much less sickling of SCT RBCs under severe hypoxia using this method compared to the previous method used in Figure 1 (data not shown), most likely reflecting the difference in duration of deoxygenation in the two assays. To evaluate the antisickling effect of GBT440, SCT blood (36% Hct, ~1.8 mM Hb) was incubated with various concentrations of GBT440 for 1 h prior to deoxygenation in the Hemox analyzer. The X-ray structure of GBT440 bound to HbS suggests that GBT440 binds in a 1:1 ratio to Hb tetramer. 14 Assuming all of GBT440 is available to bind Hb in the context of the RBC, then GBT440 concentrations of 0.5, 1.0 and 1.8 mM correspond to a calculated Hb modification (%HbMod) of 30, 60 and 100%, respectively. GBT440 produced a concentration-dependent left shift in the OEC relative to untreated SCT blood indicating that GBT440 increased the Hb-O 2 affinity of SCT blood ( Figure 3A) . Moreover, GBT440 reduced the percentage of sickled SCT RBCs relative to untreated control during deoxygenation ( Figure 3B ). Of note, at 20 mm Hg, 30% HbMod with GBT440, which was well tolerated in both healthy subjects and SCD patients in a Phase1/2 clinical trial (NCT02285088), was sufficient to prevent sickling in contrast to the untreated control SCT blood which had 7% sickled RBCs. These data show that GBT440 inhibits sickling of SCT RBCs under extreme hypoxic conditions in vitro and suggest that GBT440 may have the potential to reduce exertional sickling in SCT individuals. Unlike SCD, where patients are usually anemic and have reduced hematocrits (~20% Hct), SCT individuals have normal hematocrits (>35% Hct), thus 7% sickled cells represents a relatively larger number of circulating sickled cells in SCT compared with SCD.
GBT440 inhibits sickling of sickle cell trait blood under conditions mimicking a combination of hypoxia, dehydration and acidosis As previously mentioned, the difference in the ability of SSRBCs and SCT RBCs to sickle reflects the difference in their respective pathophysiology. Strenuous exercise at higher altitudes where the fraction of inspired oxygen is less than at sea level (~21% O 2 or >105 mm Hg) induces severe hypoxemia, metabolic acidosis, hyperthermia, and red-cell dehydration, all of which are conditions that lead to increased sickling of SCT RBCs. We next evaluated whether GBT440 could inhibit sickling of SCT blood under conditions mimicking a combination of hypoxia, dehydration and acidosis. Sickling of SCT blood was measured in hypertonic phosphate buffer at a pH of 6.9 to mimic extreme dehydration and acidosis under hypoxic conditions in the Hemox analyzer. As shown in Figure 4A , the OEC of SCT blood suspended in hypertonic phosphate buffer (pH 6.9) is right-shifted relative to isotonic phosphate buffer (pH 7.4). The right-shift in the OEC is attributed to the decrease in pH from 7.4 to 6.9 indicating a decrease in Hb-O 2 affinity in response to increased H+ ion concentration, a phenomenon referred to as the Bohr effect. 21 Compared to normal pH conditions (pH 7.4), more deoxy-HbS molecules are formed at every level of hypoxia under lower or more acidic pH conditions which leads to increased polymerization and sickling. In addition, RBCs dehydrate when suspended in a hypertonic medium. Dehydration reduces the RBC volume due to loss of water and as a result increases Hb concentration, which leads to increased polymerization and sickling. 22 The percentage of sickled SCT RBCs increased drastically in hypertonic phosphate buffer with pH 6.9 compared to isotonic phosphate buffer with pH 7.4 ( Figure 4B and C) . In addition, GBT440 produced a concentration-dependent left shift in the OEC relative to untreated SCT blood in the hypertonic phosphate buffer (Figyre 5A) indicating a dose-dependent increase in Hb-O 2 affinity. Most importantly, GBT440 dose-dependently decreased the number of sickled SCT RBCs in hypertonic phosphate buffer with pH 6.9 ( Figure 5B ). These results indicate that GBT440 inhibits in vitro sickling of SCT RBCs under conditions mimicking extreme hypoxia, dehydration and acidosis. Collectively, these results suggest that GBT440 may inhibit sickling of SCT blood in vivo under conditions that promote sickling such as during strenuous exerecise.
Discussion
Although SCT is considered a benign condition, activities such as strenuous exercise can lead to sickling-related complications, including death. 1, 23 There is currently no therapeutic option to manage or prevent sickling-related complications in SCT. In this study, we determined the ability of GBT440, a molecule that is being developed for the treatment of SCD, to inhibit in vitro sickling of SCT RBCs under various conditions. We found that SCT RBCs remain unsickled under resting hypoxic conditions but sickled under severe hypoxic conditions. While the duration of exposure of SCT RBCs to hypoxia in this experiment is nonphysiological, the results are consistent with the observation that under normal circumstances (such as at rest or during mild exercise), SCT individuals do not experience significant RBC sickling events but may do so under stressful conditions such as during strenuous exercise at high altitude. 8 These data also suggest that under stressed conditions, HbA alone may not be enough to inhibit polymerization of deoxy-HbS in SCT RBCs. Under more physiologically relevant temporal/deoxygenation conditions, sickling of SCT RBCs increased with increasing hypoxia even though the level of sickling was relatively low compared to that of SCD blood under the same conditions. Nevertheless, GBT440 dose-dependently reduced the number of sickled SCT RBCs under all levels of hypoxia evaluated.
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In SCT, renal abnormalities are among the most common complications. 1, 3 The renal medulla of the kidneys is an acidotic environment characterized with low oxygen tension and high interstitial osmolality. 3 Extensive sickling may cause vaso-occlusion and medullary microinfarctions. 3 Additionly, strenuous physical exertion at high altitudes may induce severe hypoxemia, metabolic acidosis, hyperthermia, and or red-cell dehydration, all of which promote exertional sickling potentially leading to serious morbidity. 3, 4, [8] [9] [10] We determined the ability of SCT RBCs to sickle under in vitro conditions of hypoxia, acidosis and dehydration. The results showed that SCT RBCs sickled more readily and extensively under these conditions and GBT440 reduced sickling in a dose-dependent manner.
Together, these data demonstrate that GBT440 may have the potential to prevent in vivo sickling and sickling-related complications under strenuous conditions in individuals with sickle cell trait.
